| Compound | AHK-Cu |
|---|---|
| Category | Copper-binding tripeptide (cosmetic) |
| Class | Other Injectables |
| Evidence tier | Minimal evidence |
| WADA status | Not individually listed; verify current status if subject to testing |
| Sold on this site | No — this is a reference database |
Overview
AHK-Cu — a copper-binding tripeptide (cosmetic) — sits in the "Minimal evidence" tier of this catalog. There is little or no formal study of this compound. Claims rest on anecdote, theory, or very early-stage work; risk data are absent by definition.
A copper-binding tripeptide used in cosmetic formulations, studied mainly in vitro for effects on hair-follicle and dermal cells.
Mechanism of Action
AHK-Cu is proposed to deliver copper to dermal and follicular cells, supporting collagen and growth-signaling in culture.
Research and Evidence
Evidence is cell-culture and small cosmetic studies; no clinical trial standard evidence.
Safety and Side Effects
Topical cosmetic record acceptable; injectable use unstudied.
Frequently Asked Questions
What is the evidence tier of AHK-Cu?
AHK-Cu is graded "Minimal evidence" on this site. There is little or no formal study of this compound. Claims rest on anecdote, theory, or very early-stage work; risk data are absent by definition.
Is AHK-Cu an approved medicine?
No. Minimal evidence means the compound has not reached universal regulatory approval; the tier description above explains exactly what level of evidence exists.
Where can I read the primary studies for AHK-Cu?
The references section at the end of this entry links the key primary sources — regulator labels, trial registrations, and peer-reviewed papers. Our "How to Read a Peptide Study" guide explains how to evaluate them.
References
- ClinicalTrials.gov — search for AHK-Cu studies. [source]
Evidence tier: Minimal evidence · Last reviewed: 2026-09-05 · Sources cited below.